A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
NCT07399171 · NOT YET RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Halia Therapeutics Inc. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Halia Therapeutics Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Halia Therapeutics Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Halia Therapeutics Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.